Back to Resources
Market Highlights
-
Allogene Therapeutics highlighted emerging clinical and regulatory momentum for ALLO-329 in myositis.
-
Priovant Sciences highlighted key clinical and regulatory developments for brepocitinib in dermatomyositis.
-
AstraZeneca announced expanded clinical development of Saphnelo in myositis alongside continued HCP education.
-
Argenx highlighted encouraging new data for Vyvgart and its potential expansion in myositis.
Questions about this SnapShot or other markets?
U.S. MARKETS
Christine Alongi
alongi@dtwresearch.com
GLOBAL MARKETS
Robin Cefalo
cefalo@dtwresearch.com
SOCIAL MEDIA MARKETS
Andrew Carney
carney@dtwresearch.com